Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: To evaluate the cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma (ESCC) from the perspective of the Chinese health service system.
Methods: A partitioned survival model was constructed to simulate quality-adjusted life years and incremental cost-effectiveness ratios over a patient's lifetime based on a phase III clinical trial.
Results: Sintilimab plus chemotherapy increased by 0.316 QALY and 0.285 QALY with the additional cost of $5692 and $5269, which led to the ICER of $18000/QALY and $18519/QALY gained in the overall population and the patients with CPS ≥ 10, respectively.
Conclusions: Compared with chemotherapy alone, sintilimab may be a cost-effective first-line treatment choice for locally advanced or metastatic ESCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14737167.2024.2410248 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing the Efficacy and Safety of IC-ICCRT-IO With CT-CCRT for Unresectable Locally Advanced ESCC: A Retrospective Analysis.
J Immunother
September 2025
Department of Radiotherapy, The Affiliated Hospital of Qingdao University, Laoshan, Qingdao, Shandong, China.
The present study was designed to evaluate the efficacy and safety of induction chemotherapy combined with a PD-1 inhibitor (sintilimab) followed by concurrent chemoradiotherapy (CCRT) plus sintilimab and subsequent maintenance (IC-ICCRT-IO) in patients with unresectable locally advanced esophageal squamous carcinoma (ESCC) compared with induction chemotherapy followed by CCRT without PD-1 inhibitors (CT-CCRT) using propensity score matching (PSM). Data collected from patients with histologically confirmed, inoperable ESCC treated with IC-ICCRT-IO or CT-CCRT were retrospectively analyzed-a 1:1 PSM with a caliper of 0.05 balanced potential biases.
View Article and Find Full Text PDFAn Open-Label, Single-Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non-Small Cell Lung Cancer After First-Line PD-(L)1 Inhibitor.
Cancer Med
September 2025
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Background: Although immune checkpoint inhibitors (ICIs) have markedly improved first-line management of non-small cell lung cancer (NSCLC), many tumors eventually escape control after anti-PD-(L)1 therapy, leaving a clear therapeutic gap. Preclinical studies and preliminary clinical data suggest that coupling ICIs with anti-angiogenesis therapy can yield complementary antitumor effects. Consequently, we launched this investigation to evaluate the therapeutic benefit and tolerability of sintilimab, a PD-(L)1-blocking monoclonal antibody, together with the oral multi-target anti-angiogenesis agent anlotinib in metastatic NSCLC individuals experiencing progression after first-line PD-(L)1 inhibition.
View Article and Find Full Text PDFSafety and clinical efficacy of immune checkpoint inhibitors in pediatric hepatocellular carcinoma: a case report and review of the literature.
Front Oncol
August 2025
Department of Oncology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Background: Pediatric hepatocellular carcinoma (HCC) is rare, with surgical resection and liver transplantation as primary treatments. No standard options exist for unresectable/metastatic disease. Although immune checkpoint inhibitors (ICIs) show efficacy in adults, their pediatric safety and efficacy remain unestablished.
View Article and Find Full Text PDFLow-dose radiation and stereotactic body radiotherapy with PD-1 inhibitor sintilimab and chemotherapy for first-line treatment of locally advanced or metastatic squamous lung cancer: protocol for a randomised phase II trial (IHC002 study).
BMJ Open
August 2025
Division of Thoracic Tumor Multimodality Treatment, Cancer Center and State Key Laboratory of Biotherapy, and The National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China
Introduction: Lung cancer remains a leading cause of cancer-related deaths worldwide, with squamous lung cancer representing a significant subtype. Despite advancements in chemotherapy and immunotherapy, outcomes for patients with advanced squamous lung cancer remain suboptimal. Recent studies have shown that immunotherapy, particularly with programmed death receptor 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors, can improve survival rates, but challenges persist in achieving durable responses.
View Article and Find Full Text PDFSintilimab plus anlotinib in patients with pre-treated locally advanced or metastatic sarcoma: a prospective, single-arm, phase II clinical trial.
Cancer Immunol Res
August 2025
Shandong Cancer Hospital and Institute. Shandong First Medical University and Shandong Academy of Medical Sciences., Jinan, Shandong, China.
Advanced sarcomas have limited treatment options after standard therapy, and therefore we investigated the efficacy and safety of sintilimab plus anlotinib in this setting. Patients aged 18-75 years with advanced sarcomas and prior systemic therapy were enrolled. Patients with untreated, primary chemotherapy-resistant tumor types, such as alveolar soft part sarcoma, clear cell sarcoma, etc.
View Article and Find Full Text PDF